Palmitoyl tetrapeptide-7
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Palmitoyl tetrapeptide-7
- DrugBank Accession Number
- DB14137
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 694.919
Monoisotopic: 694.474146368 - Chemical Formula
- C34H62N8O7
- Synonyms
- N-Palmitoylrigin
- Palmitoyl-GQPR
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Buddate Reges Intensive Treatment Palmitoyl tetrapeptide-7 (0.000006 g/100mL) + Butylene glycol (5.57 g/100mL) + Hydrogenated coconut oil (4 g/100mL) + Palmitoyl oligopeptide (0.000006 g/100mL) + Shea butter (3 g/100mL) Cream Topical Buddate Co Ltd 2017-01-01 Not applicable US Buddate Reges Intensive Treatment Palmitoyl tetrapeptide-7 (0.000006 g/100mL) + Butylene glycol (5.57 g/100mL) + Hydrogenated coconut oil (4 g/100mL) + Palmitoyl oligopeptide (0.000006 g/100mL) + Shea butter (3 g/100mL) Cream Topical Buddate Co Ltd 2017-01-01 2017-01-02 US Derma Under Eye Palmitoyl tetrapeptide-7 (0.00015 mg/15g) + Hyaluronic acid (0.15 mg/15g) + Palmitoyl oligopeptide (0.0003 mg/15g) Gel Topical Pella Pharmaceuticals Co. ltd 2014-12-24 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Buddate Reges Intensive Treatment Palmitoyl tetrapeptide-7 (0.000006 g/100mL) + Butylene glycol (5.57 g/100mL) + Hydrogenated coconut oil (4 g/100mL) + Palmitoyl oligopeptide (0.000006 g/100mL) + Shea butter (3 g/100mL) Cream Topical Buddate Co Ltd 2017-01-01 Not applicable US Buddate Reges Intensive Treatment Palmitoyl tetrapeptide-7 (0.000006 g/100mL) + Butylene glycol (5.57 g/100mL) + Hydrogenated coconut oil (4 g/100mL) + Palmitoyl oligopeptide (0.000006 g/100mL) + Shea butter (3 g/100mL) Cream Topical Buddate Co Ltd 2017-01-01 2017-01-02 US Derma Under Eye Palmitoyl tetrapeptide-7 (0.00015 mg/15g) + Hyaluronic acid (0.15 mg/15g) + Palmitoyl oligopeptide (0.0003 mg/15g) Gel Topical Pella Pharmaceuticals Co. ltd 2014-12-24 Not applicable US
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Oligopeptides
- Alternative Parents
- Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Pyrrolidinecarboxamides / N-acylpyrrolidines / Heterocyclic fatty acids / N-acyl amines / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Guanidines show 9 more
- Substituents
- Aliphatic heteromonocyclic compound / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-oligopeptide / Azacycle / Carbonyl group / Carboxamide group / Carboximidamide / Carboxylic acid / Fatty acid show 27 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Q41S464P1R
- CAS number
- 221227-05-0
- InChI Key
- IHRKJQSLKLYWBQ-QKDODKLFSA-N
- InChI
- InChI=1S/C34H62N8O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-19-29(44)39-24-30(45)40-25(20-21-28(35)43)32(47)42-23-16-18-27(42)31(46)41-26(33(48)49)17-15-22-38-34(36)37/h25-27H,2-24H2,1H3,(H2,35,43)(H,39,44)(H,40,45)(H,41,46)(H,48,49)(H4,36,37,38)/t25-,26-,27-/m0/s1
- IUPAC Name
- (2S)-2-{[(2S)-1-[(2S)-4-carbamoyl-2-(2-hexadecanamidoacetamido)butanoyl]pyrrolidin-2-yl]formamido}-5-[(diaminomethylidene)amino]pentanoic acid
- SMILES
- [H]N([H])C(=O)CC[C@H](N([H])C(=O)CN([H])C(=O)CCCCCCCCCCCCCCC)C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCCN=C(N([H])[H])N([H])[H])C(O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 8253946
- 1314277
- ZINC
- ZINC000163851498
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Cream Topical Gel Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00556 mg/mL ALOGPS logP 2.8 ALOGPS logP 0.045 Chemaxon logS -5.1 ALOGPS pKa (Strongest Acidic) 3.54 Chemaxon pKa (Strongest Basic) 11.23 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 10 Chemaxon Hydrogen Donor Count 7 Chemaxon Polar Surface Area 252.4 Å2 Chemaxon Rotatable Bond Count 28 Chemaxon Refractivity 185.21 m3·mol-1 Chemaxon Polarizability 79.54 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 307.6530316 predictedDarkChem Lite v0.1.0 [M+H]+ 308.4577316 predictedDarkChem Lite v0.1.0 [M+Na]+ 306.7665316 predictedDarkChem Lite v0.1.0
Drug created at June 27, 2018 17:28 / Updated at June 12, 2020 16:53